All News
Early MRI Sacroiliac Improvement with JAK Inhibition
The TORTUGA trial tested filgotinib, a JAK1 inhibitor, in active ankylosing spondylitis (AS) patients and was shown to be both effective and capable of retarding sacroiliac (SI) joint erosions as early as 12 weeks.
Read Article
Safety and Tolerability of Subcutaneous Methotrexate
A large, single-rheumatology center analysis of oral and subcutaneous (SC) methotrexate (MTX) use in daily clinical practice suggests that SC MTX has fewer drug discontinuations and is better tolerated compared to other DMARD therapies.
Read Article
RheumNow Podcast – Saphnelo (Anifrolumab) Approved for Lupus (8.6.2021)
It was a banner week at the FDA; a new drug approval you should know about; a lot of information about pregnancy and safety; and an interesting case plus a question from one of our readers submitted via Back Talk. This and more in this week's podcast. Let's dive in.
Read Article
Delays in Joint Replacement as JIA Patients Reach Adulthood
A retrospective cohort study examined the need for joint replacement surgery in juvenile idiopathic arthritis (JIA) and showed there has been a trend to delay arthroplasty over time. The JIA category, year of implant, and presence of complications significantly affected implant survivorship.
Read Article
Rheumatic Flares Uncommon After COVID Vax
Post-vaccination disease flares were uncommon among patients with rheumatic and musculoskeletal diseases who were inoculated against COVID-19, researchers found.
Read Article
Rheumatoid Arthritis Offspring Show Normal School Performance
A prospective, longitudinal study of the cognitive development of children born to mothers with rheumatoid arthritis (RA) demonstrates normal development as measured by comparative school test scores.
Read Article
FDA Approves Anifrolumab in SLE
AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the the Food and Drug Administration (FDA) for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.
Read Article
Fibromyalgianess Influences Steroid Persistence
"Fibromyalgianess" is highlighted as a risk factor for undue, extended glucocorticoid use in rheumatoid arthritis (RA) patients, according to Wallace and colleagues in Rheumatology.
Read Article
RheumNow Podcast – Psoriatic Arthritis Without Psoriasis (7.30.2021)
How much psoriasis do you need to have in order to have psoriatic arthritis? This plus a review of rheumatology and COVID news from the past week on RheumNow.com.
Read Article
Shingles Risk with JAK Inhibitors and Other Biologics
Registry data suggests an increased risk of herpes zoster (HZ, shingles) in rheumatoid arthritis (RA) patients taking JAK inhibitors (JAKi) but also with other biologic DMARDs, compared to csDMARDs.
Read Article
No Cancer Risk with TNF Inhibitors in Rheumatoid Arthritis
The ARTIS Study Group has published their analysis of (non-skin) cancer risk in rheumatoid arthritis, claiming the overall safety of biologic DMARDs and targeted synthetic DMARDs (tsDMARDs).
Read Article
Combo Methotrexate and Leflunomide Safety in RA
Methotrexate and leflunomide (LEF) are the most widely prescribed DMARDs worldwide; yet biologic DMARDs are the newest and best selling agents for rheumatoid arthritis worldwide.
Read Article
CDC Reverses Stance on Masks
Today the Centers for Disease Control and Prevention (CDC) said that masks should be used by those vaccinated against the coronavirus in public indoor spaces in parts of the country where the virus is surging.
Read Article
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
